A

Adcock Ingram Holdings Ltd
JSE:AIP

Watchlist Manager
Adcock Ingram Holdings Ltd
JSE:AIP
Watchlist
Price: 7 480.0003 Zac Market Closed
Market Cap: 121m ZAR

ROE

15.3%
Current
Declining
by 0.4%
vs 3-y average of 15.6%

Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.

ROE
15.3%
=
Net Income
858.5m
/
Avg Total Equity
5.6B

Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.

ROE
15.3%
=
Net Income
Zac858.5m
/
Avg Total Equity
5.6B

Peer Comparison

Country Company Market Cap ROE
ZA
Adcock Ingram Holdings Ltd
JSE:AIP
121m ZAR
Loading...
US
Eli Lilly and Co
NYSE:LLY
954.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
546.2B USD
Loading...
CH
Roche Holding AG
SIX:ROG
268.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
265.4B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.6B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.4B EUR
Loading...

Market Distribution

In line with most companies in South Africa
Percentile
54rd
Based on 26 companies
54rd percentile
15.3%
Low
-1 980% — -27.8%
Typical Range
-27.8% — 41.9%
High
41.9% — 480.3%
Distribution Statistics
South Africa
Min -1 980%
30th Percentile -27.8%
Median -18.9%
70th Percentile 41.9%
Max 480.3%

Adcock Ingram Holdings Ltd
Glance View

Market Cap
121m Zac
Industry
Pharmaceuticals

Nestled in the competitive landscape of the pharmaceutical industry, Adcock Ingram Holdings Ltd. stands as a testament to resilience and evolution. Originating in South Africa, the company has built a legacy that combines a strong local presence with strategic global aspirations. Adcock Ingram’s journey is marked by an adaptive approach that blends innovation with consumer health needs. Its primary revenue streams flow from the development, manufacturing, and distribution of a wide array of healthcare products, including prescription medicines, over-the-counter formulations, and hospital medications. By maintaining a robust supply chain and nurturing partnerships both locally and internationally, the company ensures the steady availability of essential healthcare products across markets. The company’s recipe for success is enriched by a deep-rooted commitment to quality and research-driven practices. By investing in cutting-edge manufacturing facilities and a well-structured distribution network, Adcock Ingram manages to sustain efficiency and scale. This approach does not merely hinge on the core pharmaceutical business but extends to leveraging diverse consumer brands across various segments such as personal care and nutritional products. Their diverse portfolio not only mitigates risks associated with the volatile pharmaceutical industry but also aligns with the ever-evolving consumer health trends. In essence, Adcock Ingram thrives by intertwining strategic foresight with robust operational excellence, steadfastly serving the health and well-being of its customers.

AIP Intrinsic Value
Not Available
A
What is Return on Equity?
Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.
How is ROE calculated?

ROE is calculated by dividing the Net Income by the Avg Total Equity.

ROE
15.3%
=
Net Income
858.5m
/
Avg Total Equity
5.6B
What is Adcock Ingram Holdings Ltd's current ROE?

The current ROE for Adcock Ingram Holdings Ltd is 15.3%, which is below its 3-year median of 15.6%.

How has ROE changed over time?

Over the last 3 years, Adcock Ingram Holdings Ltd’s ROE has decreased from 16.1% to 15.3%. During this period, it reached a low of 13.8% on Dec 31, 2024 and a high of 16.9% on Jun 30, 2023.

Back to Top